Biotech's 'Asset Sale' Trap: Build Generational Companies Instead
Jake Becraft critiques biotech's short-term 'asset sale' model. Learn why patient capital and a long-term vision like Amazon or SpaceX beat quick exits.
Reimagining Biotech with Jake Becraft of Strand Therapeutics — Tim’s Founder Kitchen
With Tim Ferriss, Jake Becraft, Phil Strandwitz, Jaime · Sunday, June 7, 2026
Jake Becraft, CEO of Strand Therapeutics, discusses the company's RNA genetic medicine technology for cancer, highlighting a patient's remarkable recovery from stage 4 melanoma via the abscopal effect. He critically analyzes the US biotech regulatory landscape, advocating for streamlined clinical trials, and contrasts it with faster international approaches. Becraft also shares lessons on effective advocacy and "platform therapeutics" as a long-term strategy, drawing parallels to companies like SpaceX and Amazon.
Genetic Medicine: 'Delivery' is Potency, Specificity, & Transport
Jake Becraft reveals why genetic medicine's 'delivery' problem isn't one issue, but three: potency, specificity, and the transport mechanism. Apply his framework.
Good Drug vs. Good Product: Becraft's Biotech Delivery Paradox
Jake Becraft of Strand Therapeutics reveals the 'Genetic Medicine Development Paradox,' pushing founders to solve for product scalability beyond just discovery.
Good Drug vs. Good Product: Becraft's Biotech Scaling Rule
Jake Becraft reveals why a drug that works for one patient can still be a terrible product for millions. Learn his rule for scalable biotech impact.
Make Them Care First: Biotech's Policy Influence Blueprint
Jake Becraft's framework for founders: move policymakers and investors from skepticism to consensus by telling urgent stories, offering solutions, not just complaints.
Strand’s RNA Drug Teaches Cancer Cells to Self-Destruct
Jake Becraft reveals how Strand Therapeutics’ RNA genetic medicine programs cancer cells to activate the immune system, causing widespread tumors to disappear.
Reprogramming Cancer: Strand's RNA Triggers System-Wide Response
Jake Becraft reveals how Strand Therapeutics uses RNA to make cancer cells fight themselves. Learn about the 'abscopal effect' and its implications for builders.
US Biotech: China Wins First-in-Human Trials
Jake Becraft warns US biotech is losing to China on early clinical trials. Our IND system costs millions and takes 18+ months. See the faster CTN model.
US Biotech Losing to China: A $25M Regulatory Problem
Jake Becraft of Strand Therapeutics reveals why US biotech trials cost $25M and 18 months, ceding ground to China. He proposes a new CTN system to accelerate drug testing.